View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 8, 2021updated 11 Jul 2022 2:22pm

Inhalon initiates Phase I Covid-19 inhaled therapy trial

The trial is being conducted along with Celltrion and will analyse inhaled IN-006’s safety and tolerability in healthy subjects. 

Inhalon Biopharma has initiated the Phase I clinical trial of its inhaled drug, IN-006, in healthy individuals, with the dosing of the first subject.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

IN-006 is a muco-trapping form of a human monoclonal antibody, regdanvimab (CT-P59).

Being carried in partnership with Celltrion, the placebo-controlled, dose-escalation Phase I trial will analyse the safety and tolerability of inhaled IN-006.

In May this year, Inhalon received $7m award from the US Army Medical Research & Development Command (USAMRDC) to assess inhaled IN-006 in the Phase I trial.

The muco-trapping antibody platform of Inhalon traps the virus in airway mucus, hindering the local spread of infection.

Furthermore, it can rapidly remove the virus from the lungs using the natural ability of the body to clear mucus.

Inhaled treatment can be administered by people at home and broaden vital treatment supplies to more patients by lowering the dosage required.

It also lowers the requirement on healthcare workers and infusion clinic space needed for intravenous (IV) therapies.

Inhalon Biopharma president and CEO John Whelan said: “Inhalon’s muco-trapping antibody technology is the only therapeutic modality that can actively clear infectious virus from the lungs via natural mucus clearance, thereby eliminating the source of inflammation and viral spread.

“Combining Inhalon’s inhaled, muco-trapping platform with Celltrion’s highly effective anti-SARS-CoV2 antibody will likely create a new treatment that patients can self-administer to free up valuable healthcare resources.”

Celltrion has already obtained emergency use authorization (EUA) for the IV formulation of regdanvimab to treat Covid-19 in various nations globally.

In a Phase III trial conducted by Celltrion, regdanvimab showed to substantially lower the risk of Covid-19-associated hospitalisation or mortality by 72% in people who are at increased risk of disease progression.

The drug offered a 70% reduced risk in the trial for all subjects.

In addition, regdanvimab was found to be efficacious against variants including the Alpha, Beta, Gamma and Delta variants of SARS-CoV-2 in in vitro or in vivo studies.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena